All News

An outpatient multiple myeloma clinic benefited substantially from employing a clinical pharmacist.

Here's this week's roundup of the latest coronavirus-related news.

“Data collection is ongoing with additional analyses planned to look at patient and provider perception of COVID-19 impact on cancer care.”

SOLO-2 is the first phase 3 trial to provide overall survival (OS) data on maintenance PARP inhibitor therapy.

The study is the first of its kind on a national scale to show the benefit of Medicaid expansion on cancer mortality rates.

CMS is reducing insulin copays for seniors who are eligible for Medicare via an executive order from President Donald Trump.

The findings, which were presented virtually in the 2020 ASCO Virtual Scientific Program, included the association between treatment with hydroxychloroquine plus azithromycin and increased risk of death.

Months after FDA said it was investigating the carcinogenic ingredient NDMA in metformin products, the agency’s testing has found elevated levels of NDMA in extended release metformin, but not in the immediate release formulation. 

The American Society of Clinical Oncology (ASCO) recently released a detailed guidance to oncology practices

In a new consensus paper, experts emphasized that high doses of vitamin D supplementation have no current benefit in the prevention or treatment of COVID-19.

Although several therapeutic agents have been evaluated for the treatment of COVID-19, none have yet shown to be effective.

Results from a phase 3 study showed that galcanezumab-gnlm (Emgality, Eli Lilly) significantly improved work productivity and health and well-being between migraine attacks.

Officials with the FDA have granted priority review for mepolizumab (Nucala, GlaxoSmithKline) in the treatment of patients with hypereosinophilic syndrome.

Filgotinib achieved all primary end points of the phase 2b/3 study in patients with moderate-to-severe ulcerative colitis.

Dupilumab (Dupixent, Sanofi and Regeneron) is the first biologic medicine approved for treatment of moderate-to-severe atopic dermatitis.

In an interview with Drug Topics®, Richard Scholz, chief strategy officer of ERxDirect, explained the prominence of telemedicine during the COVID-19 pandemic and the lasting implications of new technologies during unprecedented times.

New data showed that treatment with hydroxychloroquine was associated with increased mortality in hospitalized patients with COVID-19. 

Women and older adults are underrepresented in clinical trials evaluating cholesterol medications, according to a new study published in JAMA Network Open.

Migraine is one of the most common neurologic disorders in children and adolescents with a prevalence of 7.7%.

Officials with the FDA have approved Octapharma’s investigational new drug (IND) application for intravenous immune globulin (IVIG) (Human, Octagam 10%) therapy.

A close look at their potential to interact with other medications is required to limit the risk of adverse outcomes for patients.

Here's a roundup of the latest coronavirus-related news.

In part 2 of our interview, Mike Johnston, founder and chief executive officer of the National Pharmacy Technician Association (NPTA), discussed the results of their recent survey, which found that many pharmacists and pharmacy technicians feel unsafe from COVID-19 at their workplaces.

AstraZeneca has received funds exceeding $1 billion from the US Biomedical Advanced Research and Development Authority (BARDA) for the development, production, and delivery of the University of Oxford’s coronavirus disease 2019 (COVID-19) vaccine candidate.

Supplementation during pregnancy can have potential positive health outcomes for offspring.

The US Department of Health & Human Services partners with Phlow Corporation team to prevent drug shortages during the current pandemic and in future public health emergencies.

A new guidance from the US Department of Health & Human Services (HHS) paves the way for pharmacists nationwide to administer coronavirus disease 2019 (COVID-19) tests.

Mike Johnston, founder and chief executive officer of the National Pharmacy Technician Association (NPTA), joined Drug Topics® to discuss their recent survey that pinpointed where pharmacists are feeling most unprotected during the pandemic.

Approximately 20% to 30% of men with metastatic castration-resistant prostate cancer have HRR gene mutation.

A new review in JAMA Pediatrics looks at the current status of PrEP uptake among adolescents aged 13 to 19 years who are at risk for HIV.